Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of TroVax with pemetrexed and cisplatin for pleural mesothelioma (SKOPOS)
This trial looked at a vaccine called TroVax alongside chemotherapy for mesothelioma in the lining of the lungs (pleural mesothelioma).
More about this trial
In this trial, researchers wanted to see if having TroVax as well as chemotherapy is useful. TroVax is a type of immunotherapy called a vaccine. Vaccines help the immune system to recognise and attack certain cells.
Many mesothelioma cells carry a protein called 5T4. The research team hoped that TroVax would stimulate the immune system to recognise and kill mesothelioma cells that carry the 5T4 protein. This is called an anti 5T4 immune response.
The aim of the trial was to see if TroVax can stimulate the immune system to help recognise 5T4 mesothelioma cells.
Summary of results
- 16 people had all 9 doses as of TroVax as planned
- 19 people had all 4 cycles of chemotherapy as planned
- not gone away completely in anyone
- got a bit better in 4 people (17%)
- stayed the same in 16 people (70%)
- got worse in 3 people (13%)
How to join a clinical trial
Dr Jason Lester
June Hancock Mesothelioma Research Fund
NIHR Clinical Research Network: Cancer
Velindre Cancer Centre Stepping Stones Appeal
Velindre NHS Trust
Wales Cancer Trials Unit